Immunotherapy Drugs Market

Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025

Report Code: PH 3926 May, 2020, by marketsandmarkets.com
COVID-19

Get in-depth analysis of the COVID-19 impact on the Immunotherapy Drugs Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Immunotherapy Drugs Market

Request For Special Pricing

[176 Pages Report] The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. The growth of this market is majorly attributed to the rising prevalence of target diseases, increasing demand for monoclonal antibodies and biosimilars, increasing adoption of immunotherapy drugs over conventional treatments, and a favorable approval scenario. However, timeline issues, side-effects, and manufacturing complexities and a high attrition rate in the product development cycle are expected to challenge market growth.

Immunotherapy Drugs Market, by Region

The monoclonal antibodies segment accounted for the largest share of the immunotherapy drugs market, by type, in 2019

Based on type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapies. The monoclonal antibodies segment accounted for the largest share of the global immunotherapy drugs market in 2019. This large share can be attributed to their high specificity and fewer side-effects, increasing focus on personalized medicines, initiatives by industry players, and the rising target disease incidence and patient pool.

By therapeutic area, cancer accounted for the largest market share in 2019

On the basis of therapeutic area, this market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the global immunotherapy drugs market, by therapeutic area, in 2019. The large share of this segment can be attributed to the growing prevalence of cancer, rising research activity in this area, and reimbursement coverage for immunotherapies for oncology.

By end user, hospitals to witness the highest growth during the forecast period

On the basis of end users, the global immunotherapy drugs market is broadly segmented into hospitals, clinics, and other end users. Hospitals accounted for the largest share of the global market in 2019. This segment is also estimated to grow at the highest CAGR of 12.1% over the forecast period. The large share of this segment can be attributed to the rising spending by hospitals for immunotherapies and the demand for advanced treatments currently only provided by hospitals.

Immunotherapy Drugs Market, by Region

North America dominates the immunotherapy drugs market, by region

North America accounted for the largest share of the immunotherapy drugs market in 2019. The large share of this region in the global market can be attributed to the increasing prevalence of cancer and autoimmune diseases, rising demand for safer cancer therapies, increasing number of approvals from the FDA, and the introduction of favorable reimbursement policies. The Asia Pacific market is expected to grow at the highest rate during the forecast period.

Key Market Players

The major players in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), Merck & Co (US), Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany), BioNTech SE, Genmab, Gilead Sciences, NBE Therapeutics, Teva Pharmaceuticals, Bayer, and Bristol-Myers Squibb.

Scope of the Report:

Report Metric

Details

Market size available for years

2018–2024

Base year considered

2019

Forecast period

2020–2025

Currency

USD

Segments covered

Type, therapeutic area, end user, and region

Geographies covered

North America, Europe, Asia, and the Rest of the World

Companies covered

F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), Merck & Co Inc. (US), Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), Immatics Biotechnologies (Germany), BioNTech SE (Germany), Genmab A/S (Denmark), Gilead Sciences, Inc. (US), NBE Therapeutics (UK), Teva Pharmaceuticals (Israel), Bayer AG (Germany), Bristol-Myers Squibb (US), Incyte Corporation (US), Juno Therapeutics (US), Bluebird Bio (US), Celldex Therapeutics, Vitaeris (Canada)

The research report categorizes the immunotherapy drugs market into the following segments and subsegments:

Type

  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Interferons & Interleukins
  • Other Immunotherapies

Therapy Area

  • Cancer
  • Autoimmune & Inflammatory Diseases
  • Infectious Diseases
  • Other Therapeutic Areas

End User

  • Hospitals
  • Clinics
  • Other End Users

Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Recent Developments

  • In 2019, Novartis International AG inaugurated a manufacturing facility for cell and gene therapies in Stein, Switzerland
  • In 2019, Amgen launched MVASI (bevacizumab-awwb) and KANJINTI (trastuzumab-anns) in the US
  • In 2019, Gilead Sciences, Inc. and Humanigen, Inc. (US) collaborated to jointly conduct a study of lenzilumab with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma

Critical questions answered in the report:

  • How will the current technological trends affect the immunotherapy drugs market in the long term?
  • What are the factors contributing to the growth of the monoclonal antibodies segment in the immunotherapy drugs market?
  • Which regions are likely to grow at the highest CAGR?
  • What are the challenges hindering the adoption of immunotherapy drugs solutions?
  • What are the growth strategies being implemented by major market players?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 16)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET SCOPE
           1.2.1 MARKETS COVERED
           1.2.2 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 19)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Breakdown of primary sources
    2.2 MARKET SIZE ESTIMATION
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 28)

4 PREMIUM INSIGHTS (Page No. - 31)
    4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW
    4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE (2019)
    4.3 GEOGRAPHIC SNAPSHOT OF THE IMMUNOTHERAPY DRUGS MARKET
    4.4 PIPELINE OF PHASE 2/3 IMMUNOTHERAPY DRUGS

5 MARKET OVERVIEW (Page No. - 42)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing adoption of immunotherapy drugs over conventional treatment regimens
                    5.2.1.2 Rising prevalence of cancer and autoimmune & infectious diseases
                    5.2.1.3 Increasing demand for monoclonal antibodies and biosimilars
           5.2.2 RESTRAINTS
                    5.2.2.1 Timeline issues, side-effects, and manufacturing complexities
                    5.2.2.2 High attrition rate in the product development cycle
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increased demand for personalized medicines
                    5.2.3.2 High scope for growth in emerging economies
                    5.2.3.3 Development of affordable nanoparticles for deploying immunotherapies
           5.2.4 CHALLENGES
                    5.2.4.1 High cost of immunotherapy treatment, regional disparities, and lack of insurance coverage
                    5.2.4.2 Side-effects and low efficacy of immunotherapy drugs
                    5.2.4.3 Lack of awareness
                    5.2.4.4 Delays in diagnosis and treatment
           5.2.5 IMPACT OF THE COVID-19 PANDEMIC ON THE IMMUNOTHERAPY DRUGS MARKET

6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE (Page No. - 51)
    6.1 INTRODUCTION
    6.2 MONOCLONAL ANTIBODIES
           6.2.1 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019
    6.3 CHECKPOINT INHIBITORS
           6.3.1 CHECKPOINT INHIBITORS MARKET TO GROW OWING TO THEIR WIDE APPLICABILITY IN NUMEROUS CANCER TREATMENTS
    6.4 INTERFERONS & INTERLEUKINS
           6.4.1 INTERFERONS & INTERLEUKINS USE THE PATIENT’S IMMUNE SYSTEM, WHICH PROVIDES SIGNIFICANT BENEFITS
    6.5 OTHER IMMUNOTHERAPIES

7 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA (Page No. - 57)
    7.1 INTRODUCTION
    7.2 CANCER
           7.2.1 MALIGNANT CANCERS
                    7.2.1.1 Malignant cancers held the largest share of the immunotherapy drugs market in 2019
           7.2.2 BENIGN CANCERS
                    7.2.2.1 Availability of a range of drugs for benign cancer treatment supports market growth
    7.3 AUTOIMMUNE & INFLAMMATORY DISEASES
           7.3.1 STRONG DEMAND FOR IMMUNOTHERAPIES BOLSTERS MARKET GROWTH IN THIS SEGMENT
    7.4 INFECTIOUS DISEASES
           7.4.1 INCREASING PREVALENCE AND RISE IN R&D SUPPORT MARKET GROWTH
    7.5 OTHER THERAPEUTIC AREAS

8 IMMUNOTHERAPY DRUGS MARKET, BY END USER (Page No. - 64)
    8.1 INTRODUCTION
    8.2 HOSPITALS
           8.2.1 HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY DRUGS MARKET
    8.3 CLINICS
           8.3.1 CLINICS PROVIDE FOCUSED, PRIMARY-LEVEL CARE FOR PATIENTS AND CANNOT PROVIDE ADVANCED TREATMENTS
    8.4 OTHER END USERS

9 IMMUNOTHERAPY DRUGS MARKET, BY REGION (Page No. - 68)
    9.1 INTRODUCTION
    9.2 NORTH AMERICA
           9.2.1 US
                    9.2.1.1 US holds the largest share of the North American market
           9.2.2 CANADA
                    9.2.2.1 Increasing prevalence of cancer and the growing availability of approved immunotherapy drugs to drive market growth
    9.3 EUROPE
           9.3.1 UK
                    9.3.1.1 The UK accounts for the largest share of the European market
           9.3.2 GERMANY
                    9.3.2.1 New law for biosimilars in Germany to drive market growth
           9.3.3 FRANCE
                    9.3.3.1 Initiatives by leading pharma players to drive the French market for immunotherapy drugs
           9.3.4 ITALY
                    9.3.4.1 Availability of reimbursement drives the market in Italy
           9.3.5 SPAIN
                    9.3.5.1 Increasing incidences of cancer to drive market growth during the forecast period
           9.3.6 REST OF EUROPE
    9.4 ASIA PACIFIC
           9.4.1 CHINA
                    9.4.1.1 Rising prevalence of cancer and other infectious diseases to boost the adoption of immunotherapy in China
           9.4.2 JAPAN
                    9.4.2.1 Universal health coverage boosts the market for immunotherapy drugs in Japan
           9.4.3 INDIA
                    9.4.3.1 High number of cancer specialty care hospitals to support market growth
           9.4.4 AUSTRALIA
                    9.4.4.1 Government initiatives to pave the way for the development of the Australian immunotherapy drugs market
           9.4.5 REST OF ASIA PACIFIC
    9.5 REST OF THE WORLD
           9.5.1 MIDDLE EAST & AFRICA
                    9.5.1.1 Infrastructural growth and favorable socioeconomic trends will support market growth in the MEA
           9.5.2 BRAZIL
                    9.5.2.1 Government support and player interest in Brazil will drive the market
           9.5.3 REST OF LATIN AMERICA

10 COMPETITIVE LANDSCAPE (Page No. - 109)
     10.1 INTRODUCTION
     10.2 MARKET EVALUATION FRAMEWORK
     10.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
     10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019)
             10.4.1 STARS
             10.4.2 EMERGING LEADERS
             10.4.3 PERVASIVE COMPANIES
             10.4.4 EMERGING COMPANIES
     10.5 COMPETITIVE SCENARIO
             10.5.1 KEY PARTNERSHIPS AND COLLABORATIONS
             10.5.2 KEY PRODUCT LAUNCHES
             10.5.3 KEY ACQUISITIONS
             10.5.4 KEY EXPANSIONS

11 COMPANY PROFILES (Page No. - 115)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     11.1 F. HOFFMANN-LA ROCHE
     11.2 PFIZER
     11.3 MERCK & CO
     11.4 NOVARTIS INTERNATIONAL AG
     11.5 JOHNSON & JOHNSON
     11.6 SANOFI
     11.7 GLAXOSMITHKLINE
     11.8 ABBVIE
     11.9 AMGEN
     11.10 BOEHRINGER INGELHEIM
     11.11 ASTRAZENECA
     11.12 ELI LILLY AND COMPANY
     11.13 IMMATICS BIOTECHNOLOGIES GMBH
     11.14 GENMAB
     11.15 BIONTECH SE
     11.16 GILEAD SCIENCES
     11.17 NBE THERAPEUTICS
     11.18 TEVA PHARMACEUTICALS
     11.19 BAYER AG
     11.20 BRISTOL-MYERS SQUIBB
     11.21 INCYTE CORPORATION

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 169)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 RELATED REPORTS
     12.4 AUTHOR DETAILS


LIST OF TABLES (114 TABLES)

TABLE 1 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
TABLE 2 GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005–2018
TABLE 3 COST OF KEYTRUDA, BY REGION (2018)
TABLE 4 CHECKPOINT INHIBITORS COVERED BY THE AUSTRALIAN PBS, AS OF JUNE 2019
TABLE 5 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 6 THERAPEUTIC AREAS IN WHICH MONOCLONAL ANTIBODY THERAPIES ARE APPROVED
TABLE 7 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2018–2025 (USD BILLION)
TABLE 8 CHECKPOINT INHIBITORS MARKET, BY REGION, 2018–2025(USD BILLION)
TABLE 9 INTERFERONS & INTERLEUKINS MARKET, BY REGION, 2014–2021 (USD BILLION)
TABLE 10 OTHER IMMUNOTHERAPIES MARKET, BY REGION, 2018-2025 (USD BILLION)
TABLE 11 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 12 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2018–2025 (USD BILLION)
TABLE 13 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 14 IMMUNOTHERAPY DRUGS MARKET FOR MALIGNANT CANCER, BY REGION, 2018–2025 (USD BILLION)
TABLE 15 IMMUNOTHERAPY DRUGS MARKET FOR BENIGN CANCER, BY REGION, 2018–2025 (USD BILLION)
TABLE 16 IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018–2025 (USD BILLION)
TABLE 17 IMMUNOTHERAPY DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD BILLION)
TABLE 18 IMMUNOTHERAPY DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2018–2025 (USD BILLION)
TABLE 19 IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
TABLE 20 IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION, 2018-2025 (USD BILLION)
TABLE 21 IMMUNOTHERAPY DRUGS MARKET FOR CLINICS, BY REGION, 2018–2025 (USD BILLION)
TABLE 22 IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD BILLION)
TABLE 23 IMMUNOTHERAPY DRUGS MARKET , BY REGION, 2018–2025 (USD BILLION)
TABLE 24 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018–2025 (USD BILLION)
TABLE 25 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 26 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 27 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 28 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 29 NEW CANCER CASES AND DEATHS IN THE US, BY TYPE, 2020
TABLE 30 US: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 31 US: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 32 US: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 33 US: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 34 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 35 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 36 CANADA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 37 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 38 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018–2025 (USD BILLION)
TABLE 39 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 40 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 41 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 42 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 43 UK: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 44 UK: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 45 UK: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 46 UK: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 47 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 48 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 49 GERMANY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 50 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 51 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 52 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 53 FRANCE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 54 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 55 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 56 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 57 ITALY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 58 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 59 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 60 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 61 SPAIN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 62 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 63 ROE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 64 ROE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 65 ROE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 66 ROE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 67 APAC: INCREASE IN HEALTH EXPENDITURE, BY COUNTRY (USD PER CAPITA)
TABLE 68 APAC: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018–2025 (USD BILLION)
TABLE 69 APAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 70 APAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 71 APAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 72 APAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 73 CANCER CASES IN CHINA, 2018
TABLE 74 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 75 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 76 CHINA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 77 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 78 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 79 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 80 JAPAN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 81 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 82 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 83 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 84 INDIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 85 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 86 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 87 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 88 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 89 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 90 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 91 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 92 ROAPAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 93 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 94 ROW: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018–2025 (USD BILLION)
TABLE 95 ROW: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 96 ROW: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 97 ROW: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 98 ROW: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 99 MEA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 100 MEA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 101 MEA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 102 MEA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 103 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 104 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 105 BRAZIL: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 106 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 107 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018–2025 (USD BILLION)
TABLE 108 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018–2025 (USD BILLION)
TABLE 109 ROLATAM: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018–2025 (USD BILLION)
TABLE 110 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018–2025 (USD BILLION)
TABLE 111 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2016–2019)
TABLE 112 PRODUCT LAUNCHES (2016–2019)
TABLE 113 ACQUISITIONS (2016–2019)
TABLE 114 EXPANSIONS (2016–2019)


LIST OF FIGURES (34 FIGURES)

FIGURE 1 RESEARCH DESIGN
FIGURE 2 PRIMARY SOURCES
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE
FIGURE 6 DATA TRIANGULATION METHODOLOGY
FIGURE 7 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY TYPE (2020)
FIGURE 8 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY THERAPEUTIC AREA, 2020 VS. 2025 (USD BILLION)
FIGURE 9 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY END USER, 2020 VS. 2025 (USD BILLION)
FIGURE 10 NORTH AMERICA DOMINATES THE MARKET, BUT APAC TO REGISTER THE HIGHEST GROWTH RATE
FIGURE 11 INCREASING ADOPTION OF IMMUNOTHERAPY DRUGS TO DRIVE THE MARKET
FIGURE 12 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET IN 2019
FIGURE 13 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE IMMUNOTHERAPY DRUGS MARKET FROM 2020 TO 2025
FIGURE 15 IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2019
FIGURE 16 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIGURE 17 APAC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIGURE 18 MARKET EVALUATION FRAMEWORK: COLLABORATIVE EFFORT WAS A PROMINENT TARGET FOR MARKET COMPANIES
FIGURE 19 IMMUNOTHERAPY DRUGS MARKET IN 2019
FIGURE 20 COMPETITIVE LEADERSHIP MAPPING: IMMUNOTHERAPY DRUGS MARKET
FIGURE 21 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2019)
FIGURE 22 PFIZER: COMPANY SNAPSHOT (2019)
FIGURE 23 MERCK & CO: COMPANY SNAPSHOT (2019)
FIGURE 24 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2019)
FIGURE 25 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
FIGURE 26 SANOFI: COMPANY SNAPSHOT (2019)
FIGURE 27 GLAXOSMITHKLINE: COMPANY SNAPSHOT (2019)
FIGURE 28 ABBVIE: COMPANY SNAPSHOT (2019)
FIGURE 29 AMGEN: COMPANY SNAPSHOT (2019)
FIGURE 30 ASTRAZENECA: COMPANY SNAPSHOT (2019)
FIGURE 31 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
FIGURE 32 GENMAB: COMPANY SNAPSHOT (2019)
FIGURE 33 BIONTECH SE: COMPANY SNAPSHOT (2019)
FIGURE 34 GILEAD SCIENCES: COMPANY SNAPSHOT (2019)

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

Secondary research involved the widespread use of secondary sources, directories, databases, white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the immunotherapy drugs market. It was also used to obtain important information about key players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply-side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the immunotherapy drugs market. The primary sources from the demand-side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

A breakdown of the primary respondents is provided below:

Immunotherapy Drugs Market, by Region

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by product, type, application, end user, and region).

Data Triangulation

After arriving at the market size, the immunotherapy drugs market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments.

Objectives of the Study

  • To define, describe, and forecast the global immunotherapy drugs market by type, therapeutic area, end user, and region
  • To provide detailed information about the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall immunotherapy drugs market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the immunotherapy drugs market in four major regions along with their respective key countries (North America, Europe, Asia, and the Rest of the World)
  • To profile key players in the global immunotherapy drugs market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments such as product launches, expansions, and R&D activities of the leading players in the immunotherapy drugs market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the immunotherapy drugs market into South Korea, New Zealand, and other Southeast Asian countries
  • Further breakdown of the European immunotherapy drugs market into Italy, Spain, Belgium, and the Netherlands.
Report Code
PH 3926
Published ON
May, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immunotherapy Drugs Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home